Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its appointment of David L. Tousley, CPA, MBA, as a new independent director. Tousley replaces William Garner, M.D., who stepped down from the company’s board of directors in connection with his investment in Tryp’s previously announced non-brokered private placement. “In keeping with the EGB Ventures Charter, we are always working towards our goal of developing world-class, independent boards of directors at our public portfolio companies. With Tryp now funded well into 2022 and Dave joining the board, I believe it is the appropriate time for me to step down from the Tryp board,” said Dr. Garner in the press release. “As a co-founder of Tryp, I have always believed that the company will be at the forefront of a new treatment paradigm for neuropsychiatric disorders, including pain and binge eating, and with my most recent investment in the company I have reiterated that belief and my continuing support of the company.”
To view the full press release, visit https://ibn.fm/H6hBo
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs. Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN”(TM)) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and binge eating disorder, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.